For example, platelet-derived LPAs trigger the degranulation of neutrophils [58] that contribute to MS pathology [30] and a recent study observed a reduction of EAE manifestations with an autotaxin inhibitor that blocks its catalytic phosphodiesterase activity [55]. Here, ENPP2 is linked to myeloid sarcoma.